Wirkstoffe & Arzneimittelsicherheit

Nebenwirkungen · Incresync

Incresync 12.5 mg/30 mg film-coated tablets Incresync 25 mg/30 mg film-coated tablets Incresync 25 mg/45 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 11

HOS-124704 · Präparat HOS-095913

System organ class Frequency of adverse reactions Adverse reaction Alogliptin Pioglitazone Incresync Infections and infestations upper respiratory tract infections common common common nasopharyngitis common sinusitis uncommon common Neoplasms benign, malignant and unspecified (including cysts and polyps) bladder cancer uncommon Immune system disorders hypersensitivity not known hypersensitivity and allergic reactions not known Metabolism and nutrition disorders hypoglycaemia common common Nervous system disorders headache common common hypoaesthesia common insomnia uncommon Eye disorders visual disturbance common macular oedema not known Gastrointestinal disorders abdominal pain common common gastroesophageal reflux disease common diarrhoea common dyspepsia common nausea common acute pancreatitis not known Hepatobiliary disorders hepatic dysfunction including hepatic failure not known Skin and subcutaneous tissue disorders pruritus common common rash common exfoliative skin conditions including Stevens- not known Johnson syndrome erythema multiforme not known angioedema not known urticaria not known bullous pemphigoid not known Musculoskeletal and connective tissues disorders myalgia common fracture bone common General disorders and administration site conditions oedema peripheral common weight increased common Renal and urinary disorders interstitial nephritis not known Investigations weight increased common alanine aminotransferase increased not known

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.